Environment

FSI scholars approach their research on the environment from regulatory, economic and societal angles. The Center on Food Security and the Environment weighs the connection between climate change and agriculture; the impact of biofuel expansion on land and food supply; how to increase crop yields without expanding agricultural lands; and the trends in aquaculture. FSE’s research spans the globe – from the potential of smallholder irrigation to reduce hunger and improve development in sub-Saharan Africa to the devastation of drought on Iowa farms. David Lobell, a senior fellow at FSI and a recipient of a MacArthur “genius” grant, has looked at the impacts of increasing wheat and corn crops in Africa, South Asia, Mexico and the United States; and has studied the effects of extreme heat on the world’s staple crops.

-

This event is part of the Asia Health Policy Program (AHPP) 2020-21 Colloquium series "Health, medicine, and longevity: Exploring public and private roles"

A collaborating network of researchers summarize preliminary results from recent harmonized surveys on the impact of COVID-19 on individuals living with diabetes and hypertension, focusing on their access to medication and other care, loss of household income, (non)adherence to treatment, and worsening of symptoms. Researchers from China, India, Korea, and Thailand discuss empirical results from data gathered in the last few months. Understanding to what extent lapses in medication or other treatment have occurred, and whether telehealth or other options are associated with better outcomes, may enable locally tailored, evidence-based policy responses to help mitigate impacts on future morbidity and mortality.

Speakers
Nikhil Tandon, All India Institute of Medical Sciences
Kavita Singh, Public Health Foundation of India
Lijing Yan, Duke Kunshan University
Jianchao Quan, University of Hongkong
Daejung Kim, Korea Institute for Health and Social Affairs
Piya Hanvoravongchai, Chulalongkorn University
Wasin Laohavinij, Chulalongkorn University

Via Zoom Webinar.
Register: https://bit.ly/2H6oAhV

Nikhil Tandon All India Institute of Medical Sciences
Kavita Singh Public Health Foundation of India
Lijing Yan Duke Kunshan University
Daejung Kim Korea Institute for Health and Social Affairs
Piya Hanvoravongchai Chulalongkorn University
Shorenstein APARCStanford UniversityEncina Hall E301Stanford, CA 94305-6055
0
Visiting Scholar, 2019-20
wasin_laohavinij.jpg Ph.D.

Wasin Laohavinij joined the Walter H. Shorenstein Asia-Pacific Research Center (Shorenstein APARC) as visiting scholar with the Asia Health Policy Program for the fall quarter of 2019 from King Chulalongkorn Memorial Hospital and Chulalongkorn University, where he serves as physician and teaching assistant respectively. His research focuses on diabetes care and health service systems in Thailand.  Dr. Laohavinij received his doctorate of medicine from Chulalongkorn University in 2017.

Chulalongkorn University
Jianchao Quan University of Hong Kong
Seminars
-

This event is part of the Asia Health Policy Program (AHPP) 2020-21 Colloquium series "Health, medicine, and longevity: Exploring public and private roles"

Over the last decade, India has rapidly expanded government health insurance programs that entitle low-income households to free hospital care.  In a major policy shift away from direct public provision of healthcare, these programs contract private hospitals for service delivery. This constitutes a sizeable public subsidy delivered through private agents, but there is relatively little evidence on how private hospitals perform. Using a unique dataset on 6 million insurance claims and 15,000 patient surveys, this talk will present several key insights on the behavior of private hospitals within a large government insurance program. 1) Private hospitals manipulate coding to increase their revenues at the government's expense. 2) They also charge patients out-of-pocket for care that is supposed to be free under program rules. 3) When the government increases hospital reimbursement rates, patient charges decrease substantially. 4) However, hospitals capture approximately half the increased subsidy and this is driven by less competitive markets. The results demonstrate that hospital reimbursement rates are a key policy lever shaping hospital behavior with implications for program outcomes. Improving program performance requires a combination of stronger hospital monitoring and attention to reimbursement rates; focusing on one without the other may reduce the efficiency of public spending or worsen patient welfare. Lastly, market structure, a factor rarely taken into consideration in health policy in India, may play a role in the extent to which public subsidies benefit patients.

https://aparc.fsi.stanford.edu/asiahealthpolicy/news/postdoctoral-spotlight-radhika-jain

Image
Radhika Jain 4X4 022521
Radhika Jain is the Asia Health Policy Postdoctoral Fellow for 2019-2022 at the Walter H. Shorenstein Asia-Pacific Research Center (Shorenstein APARC).  Her research focuses on health care markets, the effectiveness of public health policy, and gender disparities in health.

She completed her doctorate in the Department of Global Health at Harvard University in 2019.  Her dissertation examined the extent to which government subsidies for health care under insurance are captured by private hospitals instead of being passed through to patients, and whether accountability measures can help patients claim their entitlements. Dr. Jain's research has been supported by grants from the Weiss Family Fund and the Jameel Poverty Action Lab (JPAL). She has worked on impact evaluations of health programs in India and on the implementation of HIV programs across several countries in sub-Saharan Africa. She also held a doctoral fellowship at the Center for Global Development.

At Shorenstein APARC, Radhika is starting new work on understanding the factors that contribute to poor female health outcomes and interventions to increase the effectiveness of public health insurance.

Via Zoom Webinar.
Register: https://bit.ly/37218gJ

Shorenstein APARC Stanford University Encina Hall E301 Stanford, CA 94305-6055
1
Asia Health Policy Postdoctoral Fellow, 2019-2022
radhika_jain.jpg Ph.D.

Radhika Jain was the Asia Health Policy Postdoctoral Fellow for 2019-2022 at the Walter H. Shorenstein Asia-Pacific Research Center (Shorenstein APARC).  Her research focuses on health care markets, the effectiveness of public health policy, and gender disparities in health.

She completed her doctorate in the Department of Global Health at Harvard University in 2019.  Her dissertation examined the extent to which government subsidies for health care under insurance are captured by private hospitals instead of being passed through to patients, and whether accountability measures can help patients claim their entitlements. Dr. Jain's research has been supported by grants from the Weiss Family Fund and the Jameel Poverty Action Lab (JPAL). She has worked on impact evaluations of health programs in India and on the implementation of HIV programs across several countries in sub-Saharan Africa. She also held a doctoral fellowship at the Center for Global Development.

At Shorenstein APARC, Radhika began new work on understanding the factors that contribute to poor female health outcomes and interventions to increase the effectiveness of public health insurance.

2019-2022 Asia Health Policy Postdoctoral Fellow
Seminars
-

This event is part of the Asia Health Policy Program (AHPP) 2020-21 Colloquium series "Health, medicine, and longevity: Exploring public and private roles"

A quarter century ago in a seminal paper, Hart, Shleifer and Vishny (NBER1996, QJE1997) developed a theory of the ‘Proper Scope of Government.’ In this webinar, Oliver Hart, 2016 Nobel Laureate, reflects on that framework and its place in economics, as well as the inspiration for his more recent work on norms and guiding principles, contracts as reference points, maximizing shareholder welfare, and exit versus voice. In discussion with Karen Eggleston, Hart answers questions posed by economists who have built upon that paper and offers insights on how the theory applies to understanding public and private roles in healthcare, education, and other publicly-financed services. With China, India, and many other emerging markets engaged in decades-long controversies about public and private roles in their health sectors, and international focus on public-private partnerships for COVID-19 response and harnessing innovation to address other global challenges, this is an opportune time to discuss how conceptually rigorous thinking can inform a sometimes divisive and ideological debate with vital implications for human welfare.


Image
Oliver Hart 021021
Oliver Hart is currently the Lewis P. and Linda L. Geyser University Professor at Harvard University, where he has taught since 1993. He is the 2016 co-recipient of the Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel, a Fellow of the Econometric Society, the American Academy of Arts and Sciences, the British Academy, and the American Finance Association, a member of the National Academy of Sciences, a Distinguished Fellow of the American Economic Association, and has several honorary degrees. Hart works mainly on contract theory, the theory of the firm, corporate finance, and law and economics. His research centers on the roles that ownership structure and contractual arrangements play in the governance and boundaries of corporations. He has published a book (Firms, Contracts, and Financial Structure, Oxford University Press, 1995) and numerous journal articles. He has used his theoretical work on firms and contracts in several legal cases. He has been president of the American Law and Economics Association and a vice president of the American Economic Association.

This keynote is part of the Stanford Asia Health Policy Program colloquium series entitled:  Health, medicine, and longevity: Exploring public and private roles

Governmental agencies and non-state actors interact within health systems in complicated and sometimes controversial ways that are vital for health and well-being. These run the gamut from developing and distributing vaccines and therapeutics for COVID-19 and mitigating the social and economic impact of the pandemic, to achieving and sustaining universal health coverage, addressing the social determinants of health, mitigating disparities, and encouraging innovations for healthy longevity, to name but a few. From the conceptual foundations to the daily reality of practitioners, this colloquium series will explore the evidence and experience of the public-private nexus in health sectors across Asia, in comparative global perspective. With colloquia throughout the academic year, the series features a keynote on February 10, 2021 from Nobel Laureate Oliver Hart, “A quarter century of ‘The Proper Scope of Government’: Theory and Applications” (dating from the 1996 NBER working paper subsequently published in the Quarterly Journal of Economics, QJE).

https://www.youtube.com/watch?v=g9JRhGpXC2Y&feature=emb_title

Via Zoom Webinar.
Register https://bit.ly/3jAvFFQ

Oliver Hart Lewis P. and Linda L. Geyser University Professor, Harvard University
Seminars
-

This event is part of the Asia Health Policy Program (AHPP) 2020-21 Colloquium series "Health, medicine, and longevity: Exploring public and private roles"

Co-sponsored by the Asia Health Policy Program and the Southeast Asia Program

Jakarta time: Friday, October 30, 2020, 7:30am - 9:00am

Apart from the 1998 Asian Financial Crisis (AFC), the current COVID-19 economic crisis is Indonesia’s most serious economic calamity in half a century with adverse impact. In March 2020, Indonesia’s poverty rate increased from 9.41% to 9.78% year on year, the equivalent of 1.28 million new people entering poverty.  By the end of 2020, it is expected that poverty rates will increase above 10%, wiping out two years of Indonesia’s poverty alleviation achievements. Social protection is key for crisis recovery. Indonesia’s social protection system has continually become stronger since the AFC. Over the past two decades, Indonesia has significantly expanded its social protection programs and coverage buttressed by a robust social registry that covers the poorest 40% of the population. The COVID-19 crisis is pushing the system to its limits. Insufficient data on Indonesians vulnerable to falling into poverty (and above the poorest 40%), coupled with response programs with complicated delivery and eligibility mechanisms, has made it challenging to deliver response-focused social protection. Dr. Sumarto will discuss whether the current social protection system is strong enough to weather the storm, especially to protect those working in the informal sector and marginal groups. Today, Indonesian policymakers have the choice to keep on following the same path and continue investing on the same social protection system, or take a radical move to reform it and make it better equipped to face future challenges.

Image
Sudarno Sumarto 102920
Sudarno Sumarto is an economist specializing in poverty reduction, social protection, labor, health, education and political economy of public policy implementation. Before joining the TNP2K, he was previously a visiting scholar at the Shorenstein Asia Pacific Research Center (APARC) at Stanford University as well as Founder and Executive Director of The SMERU Research Institute. Well-versed in leading large-scale research projects, Sudarno also provides intellectual leadership to Indonesia’s RISE country team. His research has been widely published in high-impact journals such as the Journal of Political Economy, Journal of Development Economics, and World Bank Economic Review, and has extensively contributed to policy-making by the Government of Indonesia. Sudarno earned his doctoral and master’s degrees in economics from Vanderbilt University.

 

Via Zoom Webinar.
Register https://bit.ly/30vi2jJ

Sudarno Sumarto Policy Adviser, National Team for the Acceleration of Poverty Reduction (TNP2K), Senior Research Fellow, The SMERU Research Institute.
Seminars
-

This event is part of the Asia Health Policy Program (AHPP) 2020-21 Colloquium series "Health, medicine, and longevity: Exploring public and private roles"

Hong Kong time: Friday, October 16, 2020, 8:00am - 9:15am

Gabriel Leung, one of Asia’s leading epidemiologists and Dean of Medicine at the University of Hong Kong, provides an update on the global pandemic and policy responses in Asia. Leung’s presentation draws on his deep experience in research and policy, including research that defined the epidemiology of three novel viral epidemics, namely SARS in 2003, influenza A(H7N9) in 2013 and most recently COVID-19. Leung also served as Hong Kong's first Under Secretary for Food and Health (2008-11) and fifth Director of the Chief Executive's Office (2011-2).

Image
Gabriel Leung 101520
Gabriel Leung is the fortieth Dean of Medicine (2013-), inaugural Helen and Francis Zimmern Professor in Population Health and holds the Chair of Public Health Medicine at the University of Hong Kong (HKU). He was the last Head of Community Medicine (2012-3) at the University as well as Hong Kong's first Under Secretary for Food and Health (2008-11) and fifth Director of the Chief Executive's Office (2011-2) in government.

Leung is one of Asia's leading epidemiologists and global health exponents, having authored more than 500 scholarly papers with an h-index of 66 (Scopus). His research defined the epidemiology of three novel viral epidemics, namely SARS in 2003, influenza A(H7N9) in 2013 and most recently COVID-19. He led Hong Kong government's efforts against pandemic A(H1N1) in 2009. He was founding co-director of HKU's World Health Organisation (WHO) Collaborating Centre for Infectious Disease Epidemiology and Control (2014-8) and currently directs the Laboratory of Data Discovery for Health at the Hong Kong Science and Technology Park (2020-).

Leung regularly advises national and international agencies including the World Health Organisation, World Bank, Asian Development Bank, Boao Forum for Asia, Institut Pasteur, Japan Center for International Exchange and China Centers for Disease Control and Prevention. He is an Adjunct Professor of Peking Union Medical College Hospital and Adjunct Professorial Researcher of the China National Health Development Research Center.

He edited the Journal of Public Health (2007-14), was inaugural co-editor of Epidemics, associate editor of Health Policy and is founding deputy editor-in-chief of China CDC Weekly. He currently serves on the editorial boards of seven journals, including the British Medical Journal.    

He is an elected member of the US National Academy of Medicine.

Via Zoom Webinar

Register at https://bit.ly/33jLhGO

Gabriel Leung Dean of Medicine, University of Hong Kong
Seminars
Paragraphs

COVID-19 presents humanity with not just a health crisis but also a governance crisis as leaders around the globe confront the challenges of stemming the spread of the virus. Various governments have responded in various ways to slow the transmission of the virus. Ideally, the leaders of a country should approach the crisis with a two-pronged attack. The first is to flatten the epidemic curve (epi curve), which is simply a graphical representation of the number of cases and date of onset of the illness, and the second is to raise or strengthen the capacity of the health system. 

Flattening the epi curve includes mass testing for COVID-19, which has been done in South Korea, for example. Decreasing the incidence also includes quarantine, isolation, and other social distancing strategies, which have been done by various countries in varying degrees. For example, in China, total lockdown (cordon sanitaire) was implemented in Wuhan, of the Hubei province, while in the Philippines, the entire Luzon, which consists of eight administrative regions, including the national capital region (NCR), was in total lockdown (enhanced community quarantine, or ECQ) since March 16 (World Health Organization [WHO] 2020a). Other parts of the Philippines were under different degrees of quarantine at different periods since the appearance of local transmission.

Raising the health care system capacity of a country may include, but is not limited to, training of health care workers, increasing facilities or hospitals that receive COVID patients, and providing adequate personal protective equipment (PPE).

This paper offers a brief epidemiological review of COVID-19 since its first case in China and how the hotspots for this disease evolved and changed over a relatively short period. This paper also aims to provide a short descriptive review of the existing data on COVID-19 in the Association of Southeast Asian Nations (ASEAN) region and the government response of its ten member countries, so that we can somehow draw lessons and learn from these myriad experiences as we continue to combat the spread of this dangerous pathogen. The findings in this paper are preliminary, and more rigorous analysis is expected to be performed as the data becomes more extensive and available.

All Publications button
1
Publication Type
Working Papers
Publication Date
Journal Publisher
Asia Health Policy Program working paper # 58
Authors
Marjorie Pajaron
-

This event is via Zoom Webinar. Please register in advance for the webinar by using the link below.

REGISTRATION LINKhttps://bit.ly/2xZHser

Part of APARC series COVID-19 IN ASIA: RESPONSES AND IMPLICATIONS FOR THE REGION

Co-sponsored by the Asia Health Policy Program and the Southeast Asia Program

Speakers (live and pre-recorded):

Dr. Dorairaj Prabhakaran, Professor of chronic disease epidemiology, Public Health Foundation of India, and Executive Director, Center for Chronic Disease Control.

Dr. Pham Quang Thai, Member of the Vietnam Steering Committee for COVID-19 Prevention and Control

Dr. HAC Van Vinh, Associate Professor & former Dean of Research & International Relations, Thai Nguyen University of Medicine and Pharmacy

Dr. Richard Cash, Senior Lecturer on Global Health, T.H. Chan School of Public Health, Harvard University

Dr. Radhika Jain, Asia Health Policy Postdoctoral Fellow, APARC, FSI, Stanford University

Dr. Arzan Tarapore, Research Scholar, APARC, FSI, Stanford University

How is the pandemic impacting health systems and society in south and southeast Asia? Numerous experts share their perspectives on topics ranging from COVID-19 challenges in Bangladesh, India and Vietnam, to geopolitical considerations for U.S. policy in the wider Indo-Pacific.

Via Zoom Webinar.

Register at https://bit.ly/2xZHser

Dorairaj Prabhakaran Professor of chronic disease epidemiology, Public Health Foundation of India, and Executive Director, Center for Chronic Disease Control.
Pham Quang Thai Member of the Vietnam Steering Committee for COVID-19 Prevention and Control
HAC Van Vinh Associate Professor & former Dean of Research & International Relations, Thai Nguyen University of Medicine and Pharmacy
Richard Cash Senior Lecturer on Global Health, T.H. Chan School of Public Health, Harvard University
Shorenstein APARC Stanford University Encina Hall E301 Stanford, CA 94305-6055
1
Asia Health Policy Postdoctoral Fellow, 2019-2022
radhika_jain.jpg Ph.D.

Radhika Jain was the Asia Health Policy Postdoctoral Fellow for 2019-2022 at the Walter H. Shorenstein Asia-Pacific Research Center (Shorenstein APARC).  Her research focuses on health care markets, the effectiveness of public health policy, and gender disparities in health.

She completed her doctorate in the Department of Global Health at Harvard University in 2019.  Her dissertation examined the extent to which government subsidies for health care under insurance are captured by private hospitals instead of being passed through to patients, and whether accountability measures can help patients claim their entitlements. Dr. Jain's research has been supported by grants from the Weiss Family Fund and the Jameel Poverty Action Lab (JPAL). She has worked on impact evaluations of health programs in India and on the implementation of HIV programs across several countries in sub-Saharan Africa. She also held a doctoral fellowship at the Center for Global Development.

At Shorenstein APARC, Radhika began new work on understanding the factors that contribute to poor female health outcomes and interventions to increase the effectiveness of public health insurance.

Asia Health Policy Postdoctoral Fellow, APARC, FSI, Stanford University
Arzan Tarapore Research Scholar, APARC, FSI, Stanford University
Panel Discussions
-

This event is via Zoom Webinar. Please register in advance for the webinar by using the link below.

REGISTRATION LINKhttps://bit.ly/2Kpjiww

A Discussion between Matthew Kohrman and Gan Quan, co-editors of Poisonous Pandas: Chinese Cigarette Manufacturing in Critical Historical Perspectives (Stanford University Press, 2018).

Image
gan quan

 

 

 

Gan Quan (PhD, Berkeley) is the director of Tobacco Control of the International Union Against Tuberculosis and Lung Disease. His research tackles various topics pertaining to tobacco control in China.

 

 

 

 

 

Image
mathew kohrman

 

 

 

Matthew Kohrman (PhD, Harvard) is an associate professor in Stanford’s Department of Anthropology and senior fellow by courtesy at APARC/FSI. His research brings anthropological methods to bear on the ways health, culture, and politics are interrelated.

 

 

 

 

 

 

 

 

Via Zoom Webinar.

Register at https://bit.ly/2Kpjiww

Gan Quan Director of Tobacco Control of the International Union Against Tuberculosis and Lung Disease
Matthew Kohrman Associate Professor of Anthropology, Stanford University
Panel Discussions
-

More than 80% of cardiovascular diseases (CVD) and diabetes mellitus (DM) burden now lies in low and middle-income countries. Thus, there is an urgent need to identify and implement the most cost-effective interventions, particularly in the resource-constraint South Asian settings. A 2018 systematic review evaluated the cost-effectiveness of individual-level, group-level and population-level interventions to control CVD and DM in South Asia. Of the 2949 identified studies through a search of 14 electronic databases up to 2016, 42 met full inclusion criteria. Critical appraisal of studies revealed 15 excellent, 18 good and 9 poor quality studies. Most studies were from India (n=37), followed by Bangladesh (n=3), Pakistan (n=2) and Bhutan (n=1). The economic evaluations were based on observational studies (n=9), randomised trials (n=12) and decision models (n=21). Together, these studies evaluated 301 policy or clinical interventions or combination of both. We found a large number of interventions were cost-effective aimed at primordial prevention (tobacco taxation, salt reduction legislation, food labelling and food advertising regulation), and primary and secondary prevention (multidrug therapy for CVD in high-risk group, lifestyle modification and metformin treatment for diabetes prevention, and screening for diabetes complications every 2–5 years). Significant heterogeneity in analytical framework and outcome measures used in these studies restricted meta-analysis and direct ranking of the interventions by their degree of cost-effectiveness. The cost-effectiveness evidence for CVD and DM interventions in South Asia is growing, but most evidence is from India and limited to decision modelled outcomes. There is an urgent need for formal health technology assessment and policy evaluations in South Asia and other low- and middle- income countries using local research data.

Image
kavita
I am Dr. Kavita Singh, interested in global cardiometabolic disease epidemiology and economic evaluations of interventions for prevention and control of chronic diseases in low- and middle- income countries. I am an Epidemiologist by training, and work as a research scientist at the Public Health Foundation of India. My research work has primarily focused on evaluating the long-term effectiveness and cost-effectiveness of a multicomponent quality improvement intervention (consisting of decision-support electronic health records to enhance physician’s responsiveness and care coordinators to improve patient’s adherence to therapy) in 1,146 patients with type 2 diabetes attending 10 tertiary care clinics in India and Pakistan as part of the National Heart Lung Blood Institute funded CARRS Trial. Recently, I have been awarded the Emerging Global Leader Award (K43 grant, 2019-2024), funded by the National Institutes of Health, Fogarty International Centre to conduct a research project that aims to develop and test the feasibility of a multicomponent cardiovascular quality improvement strategy for patients with established cardiovascular diseases (CVD) in India.

Kavita Singh 2019-2020 Walter H. Shorenstein Asia-Pacific Research Center Visiting Scholar
Seminars
Subscribe to Environment